ARC1779 Injection

DRUG2 trials

Sponsors

Archemix Corp.

Conditions

Carotid StenosisCerebral ThromboembolismIntracranial EmbolismThrombotic MicroangiopathyThrombotic Thrombocytopenic Purpura

Phase 2

Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy

TerminatedNCT00726544

Archemix Corp.Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura

Start: 2008-12-31End: 2011-03-31Target: 100Updated: 2009-11-26

Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy

TerminatedNCT00742612

Archemix Corp.Carotid Stenosis, Cerebral Thromboembolism, Intracranial Embolism

Start: 2009-02-28End: 2010-04-30Target: 100Updated: 2010-02-10

Related Papers

The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial.

2011-06-2386 citations